BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 22101899)

  • 1. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
    Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
    Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.
    Rizo A; Horton SJ; Olthof S; Dontje B; Ausema A; van Os R; van den Boom V; Vellenga E; de Haan G; Schuringa JJ
    Blood; 2010 Nov; 116(22):4621-30. PubMed ID: 20724541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.
    Sengupta A; Arnett J; Dunn S; Williams DA; Cancelas JA
    Blood; 2010 Jul; 116(1):81-4. PubMed ID: 20407032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
    Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
    Chu S; McDonald T; Bhatia R
    Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
    Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL
    N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.
    Waldron T; De Dominici M; Soliera AR; Audia A; Iacobucci I; Lonetti A; Martinelli G; Zhang Y; Martinez R; Hyslop T; Bender TP; Calabretta B
    Leukemia; 2012 Apr; 26(4):644-53. PubMed ID: 21960247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
    Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
    Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.
    Klucher KM; Lopez DV; Daley GQ
    Blood; 1998 May; 91(10):3927-34. PubMed ID: 9573031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
    Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
    Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.
    Supper E; Tahir S; Imai T; Inoue J; Minato N
    PLoS One; 2015; 10(7):e0134026. PubMed ID: 26218064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
    Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
    Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
    Abe A; Minami Y; Hayakawa F; Kitamura K; Nomura Y; Murata M; Katsumi A; Kiyoi H; Jamieson CHM; Wang JYJ; Naoe T
    Int J Hematol; 2008 Dec; 88(5):471-475. PubMed ID: 19039626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.